Background and objectives Chronic renal transplant dysfunction is histopathologically characterized by interstitial fibrosis and tubular atrophy. This study investigated the relative contribution of baseline donor, recipient, and transplant characteristics to interstitial fibrosis and tubular atrophy score at month 12 after renal transplantation. Results Average interstitial fibrosis and tubular atrophy score increased from 0.70 to 1.65 (P,0.001). In an adjusted multiple linear regression analysis, interstitial fibrosis and tubular atrophy score at month 12 was significantly related to donor type (donors after cardiac death versus living donor had interstitial fibrosis and tubular atrophy score+0.41, 95% confidence interval=0.05-0.76, P=0.02), baseline interstitial fibrosis and tubular atrophy, and immunosuppression regimen. Because of interaction between the latter two variables (P=0.002), results are given separately: recipients with a baseline interstitial fibrosis and tubular atrophy score of zero had a 0.60 higher score at month 12 (95% confidence interval=0.09-1.10, P=0.02) when mycophenolate mofetil-treated, whereas recipients with a baseline interstitial fibrosis and tubular atrophy score more than zero had a 0.38 higher score at month 12 (95% confidence interval=0.01-0.74, P=0.04) when sirolimus-treated. A higher score at month 12 correlated with a lower estimated GFR (r=20.45, P,0.001).
Introduction
Chronic transplant dysfunction after renal transplantation is a major cause of renal graft loss, and it is caused by immunologic and nonimmunologic factors (1) (2) (3) .
Histopathologically, it is characterized by interstitial fibrosis and tubular atrophy (IF/TA), arterio-and arteriolosclerosis, and arteriolar hyalinosis as well as glomerulopathy and mesangial matrix expansion. These characterizations can already be detected during the first year after transplantation (4) (5) (6) (7) (8) . In protocol biopsies taken early after renal transplantation, IF/TA is the most important histopathological entity associated with clinical progression of transplant failure (9) (10) (11) .
The aim of our study was to investigate whether differences in IF/TA 1 year after renal transplantation are specifically related to donor, recipient, or transplant characteristics in our patients. Because of the organ shortage, suboptimal donors are increasingly used, among which are donors after cardiac death (DCD), older donors, and donors with cardiovascular disease (12) . We and others have found that, in these so-called marginal donors, more histologic damage in the preimplantation biopsy is associated with a worse graft survival and a lower estimated GFR (eGFR) (13, 14) . To investigate a potential role for immunosuppressive regimen, we studied a consecutive group of renal transplant recipients with a tacrolimus (TAC) -based immunosuppressive regimen with mycophenolate mofetil (MMF) and sirolimus (SRL) as additional immunosuppressants.
Materials and Methods

Patients
Since April of 2003, taking protocol biopsies at the time of implantation and 12 months after transplantation is part of the routine patient care at our institution. Included in this study were all patients who were transplanted between April of 2003 and February of 2007, used a TAC-based immunosuppressive regimen, and had a functional graft 1 year after transplantation. In this period, 207 patients were transplanted with a 1-year follow-up time; 30 patients had another immunosuppressive regimen because of involvement in another trial or being highly immunized.
In total, 177 patients were transplanted and treated with TAC/SRL or TAC/MMF as immunosupression. From 61 patients, we missed either a biopsy at implantation (n=34) or a 12-month biopsy (n=27). In seven patients, one biopsy was not representative, and therefore, these patients were excluded.
The baseline characteristics of the excluded and included patients were not significantly different (data not shown).
The study was approved by the Medical Ethical Committee of the Maastricht University Medical Centre (Medical Ethical Committee number 104008).
Immunosuppression
Of the 109 recipients, 58 (53%) recipients received MMF, and 51 (47%) recipients received SRL as additional immunosuppressant.
The immunosuppressive regimen was based on the TAC arms of a previous single-center randomized controlled trial from April of 2003 to June of 2004 (15) . In that study, we compared TAC and fixed low-dose SRL with TAC/MMF or SRL/MMF in an early steroid-withdrawal regimen. Because of a high rejection rate in the calcineurin inhibitor-free group, we had to stop this study prematurely. However, because of the efficacy of both TAC arms, we continued to treat the patients consecutively in different time cohorts with TAC and either low-fixed dose SRL or MMF. The choice between TAC/SRL and TAC/MMF was only based at the time of transplantation. All recipients started TAC preoperatively at a dose of 0.1 mg/kg and postoperatively at a dose of 0.1 mg/kg two times daily. Subsequent doses were adjusted according to whole-blood trough levels as determined by HPLC with tandem mass spectrometric detection (15) . The target 12-h trough level range was 15-20 ng/ml in weeks 1 and 2, 10-15 ng/ml in weeks 3 and 4, and thereafter, 5-7 ng/ml.
Additionally, all recipients received corticosteroids for 10 days: methylprednisolon at 125 mg daily on days 0 and 1 and prednisolon at 10 mg daily from day 2 to day 10 only. Prednisolon was continued only in recipients with a high risk for rejection (defined as more than 85% panel-reactive HLA antibodies in the previous 6 months and/or a previous graft survival of less than 1 year because of immunologic reasons). In recipients with an acute rejection (any grade), prednisolon was continued or reintroduced at a dose of 10 mg/d. After 1 month, the dose of prednisolon was tapered to 5 mg daily. Recipients on SRL received fixed doses of SRL 1 mg/d as described earlier (16) . Recipients on MMF received 1000 mg MMF preoperatively and 1000 mg two times daily from day 1 on. Around day 10, a 2-hour abbreviated concentration time profile of mycophenolic acid was performed and calculated according to the formula described in the work by Pawinski et al. (17) . In case of a calculated area under the curve .30 mgzh/ml, the dose of MMF was lowered to two times daily at 500 mg (18) . No induction therapy was given.
Renal Allograft Biopsies
Protocol biopsies were procured by ultrasound-guided needle core biopsy at implantation (immediately after reperfusion) and 1 year after transplantation. Biopsies were judged representative when they contained at least five glomeruli and one interlobulairy artery. Paraffin tissue sections for light microscopy were stained by hematoxylin-eosin, periodic acid-Schiff, and periodic acid methenamine, silver methods according to standard protocols. Histopathological analysis was performed by two pathologists (C.J.P.-K. and R.J.v.S.) blinded for donor and recipient characteristics. IF/TA was scored according to the Banff 97 classification (19) . Tubular atrophy was scored as zero if absent, one if 0%-25% of biopsy, two if 26%-50% of biopsy, and three if .50% of biopsy. Interstitial fibrosis was scored as zero if 0%-5% of the biopsy was affected, one if 6%-25% of the biopsy was affected, two if 26%-50% of the biopsy was affected, and three if .50% of the biopsy was affected. IF/TA was scored as the highest score from tubular atrophy or interstitial fibrosis (range=0-3). In case of a greater than one-point difference in the scoring of IF/TA between both pathologists, the final score was settled in conference.
Agreement between observers was evaluated using intraclass correlation coefficients.
Clinical Outcome Parameters
Acute rejection was defined as any rejection treatment in the first 3 months after grafting. All rejections were confirmed by ultrasound-guided needle core biopsy. The biopsies were scored and classified using the Banff 97 schema (19) . Acute rejections with Banff grade 1A and 1B were treated with three methylprednisolon pulses (1 g intravenously on alternate days). In case of a rejection with Banff grade 2A or higher, the recipients were treated with a 10-day course of rabbit antithymocyte globulin (Fresenius, Bad Homburg, Germany). eGFR at 1 year was calculated according to the Modification of Diet in Renal Disease formula (20) . Proteinuria at 1 year was expressed as proteinuria/creatinin ratio in grams per millimole in morning spot urine. BK and cytomegalovirus infection was recorded as determined by positive PCR blood levels.
Statistical Analyses
The main outcome of this study is the IF/TA score at month 12, an ordinal variable. Next to this outcome, the significance of the change between IF/TA at implantation and month 12 was analyzed with the Wilcoxon paired test. The Shapiro-Wilk test is used to test normality of distribution in continuous variables. Next, a forward selection, multiple dummy linear regression analysis was performed with IF/TA score at month 12 as the dependent variable using the following list of 11 potential predictors: donor and recipient age (years), donor and recipient sex, a trichotomy for type of donor (DCD, donation after brain death [DBD] , or living donation [LD]), IF/TA score at implantation, cold ischemic time (hours), anastomosis time (minutes), sum score of HLA-A, B, DR mismatches (zero to six), acute rejection, and type of additional immunosuppression (SRL or MMF). There were no missing data. The search for the best-fitting regression model containing only significant associations was done. Moreover, all first-order interaction associations between IF/TA score at implantation and the 11 predictors were hierarchically tested for statistical significance. The final results (change in IF/TA score, P values, and 95% confidence interval [CI] ranges for change in IF/TA score) of the best-fitting regression model are presented. Residual analysis was performed, and plots of the studentized residuals were inspected for deviations from normality of distribution. Subgroup analysis was performed if one or more of the interactions in the regression model were statistically significant. The association between 12-month IF/TA score and both eGFR and proteinuria was measured by Spearman r and also tested using the Jonckheere-Terpstra test. The Mann-Whitney test is used to test non-normally distributed variables for differences in initial IF/TA. All statistics were performed with SPSS-pc version 16.0. A P value of ,0.05 is considered to be statistically significant.
Results
Baseline and Transplant Characteristics
Baseline and transplant characteristics of the study population are listed in Tables 1 and 2 . Donor age is the only significant difference in the demographics of donors with and without IF/TA (Table 1 ). There are no significant differences between the demographics of the two treatment groups (Table 2) . At the time of implantation, an IF/TA score of zero was found in 40 (37%) recipients, whereas 69 of 109 (63%) kidneys had an IF/TA score more than zero. Of 69 patients with damage at implantation, 63 patients had an implantation IF/TA score of one, 5 patients had a score of two, and 1 patient had a score of three.
IF/TA at Months 0 and 12
The intraclass coefficient between the two pathologists regarding the IF/TA score at months 0 and 12 is 0.74 (P,0.001). These data are better than data reported in the work by Furness et al. (21) and data reported by us previously in another study on preimplantation biopsies (22) . IF/ TA score between time of implantation and month 12 increased significantly (Wilcoxon test, P,0.001). The average IF/TA score increased from 0.70 to 1.65 between implantation and month 12. DIF/TA is dependent on IF/TA at implantation and immunosuppression. In the group of donor kidneys with IF/TA at baseline, we found that, in the TAC/ MMF group, IF/TA score increased from 1.11 to 1.56, whereas in the TAC/SRL group, IF/TA score increased from 1.09 to 1.94 ( Figure 1A ). In the group of donor kidneys without IF/TA at baseline, the TAC/MMF group showed more increase (from 0 to 1.77) than the TAC/SRL group (from 0 to 1.17) ( Figure 1B ).
TAC and SRL Levels
The TAC trough levels were comparable in the two treatment groups. In the TAC/SRL group, the mean SRL trough level at month 3 was 3.0 (SD=1.5); at month 12, the SRL trough level was 2.8 (SD=1.1).
Baseline and Transplant Parameters Related to IF/TA Score at Month 12
To investigate factors associated with IF/TA score at month 12, multiple linear regression analysis was performed using 10 potential predictor baseline parameters as discussed in Materials and Methods, Statistical Analyses. All interaction factors between baseline IF/TA and the other 11 potential predictors were tested for statistical significance. The final model included DCD versus LD and the interaction factor additional immunosuppression IF/TA at implantation as predictors (R 2 =0.17, P=0.002) ( Table 3 ). In this model, the predicted IF/TA score at month 12 was 0.41 higher for recipients who had a DCD compared with recipients with an LD (P=0.02). The following factors did not reach significance given these results: cold ischemia time (P=0.18), acute rejection (P=0.20), donor age (P=0.36), DBD versus LD (P=0.47), anastomosis time (P=0.50), donor sex (P=0.54), recipient sex (P=0.63), recipient age (P=0.72), and sum score of HLA-A, B, DR mismatches (P=0.87). The interaction effect immunosuppression3IF/TA at implantation means that the association of immunosuppression on the increase of IF/TA score is dependent on the IF/TA score at implantation.
For a better understanding of the significant interaction effect between SRL/MMF and IF/TA score at implantation, the study population was further analyzed in two groups: group 1, an IF/TA score at implantation of zero (n=40); group 2, an IF/TA score at implantation of more than zero (n=69). The overall results for the multiple linear regression analysis for group 1 are shown in Table 4 . In this group, after adjusting for type of donor, recipients on MMF as additional immunosuppressant had a 0.60-point (95% CI=0.09-1.10, P=0.02) higher IF/TA score at month 12 than recipients on SRL. In group 2, the opposite results are found: recipients on SRL had a 0.38-point (95% CI=0.01-0.74, P=0.04) higher IF/TA score at month 12 than recipients on MMF (Table 5 ). Residual analysis showed that the plots of studentized residuals of the final model were sufficiently normally distributed to allow for linear regression analysis. Final model: R 2 =0.17, P=0.002. IF/TA, interstitial fibrosis and tubular atrophy; 95% CI, 95% confidence interval; DBD, donation after brain death; LD, living donation; DCD, donation after cardiac death; SRL, sirolimus; MMF, mycophenolate mofetil.
Discussion
Our study confirms that IF/TA progression occurs during the first 12 months after transplantation as well as in kidneys with no pre-existing histologic damage (4). This progression is strongly related to use of kidneys from DCD, the pre-existent IF/TA score of the donor kidney, the type of immunosuppressive drug, and the interactive effect of the last two factors. A new finding is that the IF/TA score at month 12 is different depending on the patient's type of immunosuppression in accordance to their pre-existent IF/TA score at implantation. For recipients transplanted with a kidney without IF/TA in the implantation biopsy (i.e., IF/TA score=0), the IF/TA score at month 12 was higher in recipients on MMF (compared with SRL) as additional immunosuppressant. However, for recipients transplanted with a kidney with IF/TA in the implantation biopsy, the reverse was observed; the IF/TA score at month 12 was higher in recipients on SRL (compared with MMF) as additional immunosuppressant.
Several studies have shown that progression of IF/TA is related to immunosuppression (6, (23) (24) (25) ; however, the finding that the relationship between type of additional immunosuppressant used and progression of IF/TA score or IF/TA score at month 12 is different for normal versus abnormal histology in implantation biopsies has (to the best of our knowledge) not yet been described. This differential effect is in agreement with results from the CONVERT trial (26). In that study, conversion from calcineurin inhibitors to SRL was associated with an excellent graft survival only in recipients with a baseline GFR.40 ml/min without proteinuria, whereas inclusion of recipients with a baseline GFR,40 ml/min was discontinued prematurely because of a higher incidence of primary safety endpoints (acute rejection, graft loss, or death). Although no renal biopsies were described in that study, it is plausible that the recipients with GFR,40 ml/min had a higher IF/TA score in their kidneys. The use of SRL as additional immunosuppressant next to TAC is generally discouraged with reference to delayed graft function, worse graft survival, and graft function. The work by Gallon et al. (27) showed that the combination TAC/SRL (SRL trough levels of 7-10 mg/L) had a lower 3-year graft survival and worse renal function compared with the combination TAC/MMF. It is well known that side effects of immunosuppressive drugs are strongly related to trough levels (16, 28) . In previous reports, the SRL dose (and SRL trough levels) is much higher than the 1-mg fixed dose of SRL used in this study, with average SRL trough levels of 2.9 mg/L. Nevertheless, also in this study, IF/TA score at month 12 was higher for SRL-treated patients compared with MMF-treated patients if IF/TA was present in the implantation biopsy.
The finding that the combination TAC/SRL results in a lower IF/TA score at month 12 if the implantation biopsy is normal is supported by the randomized trial in the work by Kumar et al. (29) , in which they compared four immunosuppressive protocols: Cyclosporine/MMF versus Cyclosporine/SRL versus TAC/MMF and TAC/SRL. Recipients on SRL had the lowest IF/TA scores at 5 years. Because the majority of their donors were young standard donors, it may be expected that the number of donor kidneys with pre-existing damage was low. This study is the first time that a differential effect of SRL on IF/TA is described. The mechanism of the differential effect of SRL on IF/TA progression is not clear. The fact that SRL has a positive effect on IF/TA in undamaged kidneys is in accordance with the fact that, in mice, SRL has been shown to extend life span mediated by enhancing autophagy or downregulating mRNA translation (30) . In a damaged kidney, SRL probably cannot effectuate these positive effects. Furthermore, in recent experimental studies, SRL prevented renal injury caused by mammalian target of rapamycin complex 1 activation in the podocytes; however, progression of sclerosis was not affected if SRL was given when renal injury induced by mammalian target of rapamycin complex 1 activation in podocytes was already moderate (31) .
Analysis of the implantation biopsy showed that 63% of all kidneys and 55% of kidneys from LDs had an IF/TA score$1 at time of implantation. This finding underscores the importance of evaluation of a biopsy to investigate preexistent IF/TA, which confirms studies in marginal donors on pretransplant damage and worse graft function (11, 13, 14) . Moreover, this study included a high proportion of DCDs (41%), in which more ischemia/reperfusion damage can be expected. This result may be related to a higher IF/TA score at month 12. Next to the differential type of immunosuppressive effect, the IF/TA score at 1 year is significantly higher in DCD kidneys. DCDs have a long first warm ischemic time compared with DBDs and LDs, resulting in more ischemic reperfusion damage, a well known cause of IF/TA (5, 32, 33) .
We must acknowledge that this study has a few limitations. First, this study is a retrospective study, and the number of kidneys without baseline IF/TA was limited. Second, the Banff score of IF/TA is roughly distributed (zero to three); a more refined measurement might provide a better difference in DIF/TA.
Although the follow-up of the recipients in the current study was limited to 1 year, the fact that a higher IF/TA score at month 12 significantly correlates with lower eGFR and higher proteinuria at month 12 (both factors are well known risk factors for graft failure) (34, 35) underlines the potential clinical significance of these findings. This finding suggests that prevention of progression of IF/TA may improve long-term graft survival. However, all these results need to be further investigated and tested in future randomized, controlled trials. A potential strategy for future randomized, controlled trials may be tailoring immunosuppressive drugs in accordance with the IF/TA scoring of the (pre-) implantation biopsy.
